Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma.
Pan Y et al.Clin Chim Acta. 2018 Feb 19;480:199-205. doi: 10.1016/j.cca.2018.02.019. [Epub ahead of print].

Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple MyelomaWith Deep Responses.
Miyazaki K et al. Clin Lymphoma Myeloma Leuk. 2018 Feb 19. pii: S2152-2650(17)31288-0. doi: 10.1016/j.clml.2018.01.008. [Epub ahead of print].

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.
Gerber B et al. Haematologica. 2018 Feb 22. pii: haematol.2017.184358. doi: 10.3324/haematol.2017.184358. [Epub ahead of print].

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.
Gu C et al. Blood Cancer J. 2018 Feb 15;8(2):22. doi: 10.1038/s41408-018-0060-0.

Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma.
Zhou D et al. Clin Chim Acta. 2018 Feb 13. pii: S0009-8981(18)30070-6. doi: 10.1016/j.cca.2018.02.009. [Epub ahead of print].

In silico screening of proteins targeting circulating miRNAs for improved diagnosis of multiple myeloma.
Suyal S et al. Biochem Biophys Res Commun. 2018 Feb 12. pii: S0006-291X(18)30332-2. doi: 10.1016/j.bbrc.2018.02.103. [Epub ahead of print].

Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma.
Stecco A et al. Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434881. [Epub ahead of print].

Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
Zajec M et al. J Proteome Res. 2018 Feb 15. doi: 10.1021/acs.jproteome.7b00890. [Epub ahead of print].

N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma.
Pavo N et al. Eur J Clin Invest. 2018 Feb 8. doi: 10.1111/eci.12905. [Epub ahead of print].

Analytical validation of the Hevylite assays for M-protein quantification.
Jacobs JFM et al. Clin Chem Lab Med. 2018 Feb 5. pii: /j/cclm.ahead-of-print/cclm-2017-0817/cclm-2017-0817.xml. doi: 10.1515/cclm-2017-0817. [Epub ahead of print].

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P et al. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):152-160. doi: 10.1016/j.clml.2017.12.012. Epub 2018 Jan 5.

Functional and molecular MRI of the bone marrow in multiple myeloma.
Koutoulidis V et al. Br J Radiol. 2018 Feb 13:20170389. doi: 10.1259/bjr.20170389. [Epub ahead of print].

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myelomain Asian patients.
Byun JM et al. Cancer Med. 2018 Jan 29. doi: 10.1002/cam4.1340. [Epub ahead of print].